Phase II active comparator study with injectable RT 002 [botulinum toxin A] for the treatment of glabellar lines

Trial Profile

Phase II active comparator study with injectable RT 002 [botulinum toxin A] for the treatment of glabellar lines

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Glabellar lines
  • Focus Therapeutic Use
  • Acronyms BELMONT
  • Sponsors Revance Therapeutics
  • Most Recent Events

    • 01 Nov 2017 Results published in the Dermatologic Surgery
    • 15 Jun 2017 According to a Revance Therapeutics media release, results from this trial published in the Dermatologic Surgery journal.
    • 03 Mar 2017 According to a Revance Therapeutics media release, data will be presented at the 2017 American Academy of Dermatology (AAD) Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top